Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea E Wahner Hendrickson

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Trends in Cancer|November 10, 2017
Doubling Down on BRCA-Mutated CancerAndrea E Wahner Hendrickson, Scott H Kaufmann, Elizabeth M Swisher
Cancer Medicine|May 12, 2016
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trialsSeongseok Yun, Nicole D Vincelette, Myke R Green, et al.
Journal of Palliative Medicine|May 25, 2018
Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated PatientsJason D Doles, Kelly A Hogan, Jennifer O'Connor, et al.
Cancer Research|April 4, 2013
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA statusCatherine J Huntoon, Karen S Flatten, Andrea E Wahner Hendrickson, et al.
Investigational New Drugs|April 2, 2013
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignanciesErin Schenk, Andrea E Wahner Hendrickson, Donald Northfelt, et al.
Rare Tumors|May 7, 2021
An unusual case of aggressive malignant spread of epithelioid hemangioendotheliomaAshley D Hickman, Evandro D Bezerra, Anja C Roden, et al.
Current Treatment Options in Cardiovascular Medicine|March 3, 2018
Cardiovascular Concerns in BRCA1 and BRCA2 Mutation CarriersKelly C Gast, Paul V Viscuse, Somaira Nowsheen, et al.
Gynecologic Oncology|June 15, 2026
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomesRiham Suleiman, Shilpa Mokshagundam, Matthew S Block, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 4, 2021
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitizationUpasana Ray, Debarshi Roy, Ling Jin, et al.
Gynecologic Oncology|July 13, 2023
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?Anousheh Shafa, A Brooke Watkins, Michaela E McGree, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Trends in Cancer|November 10, 2017
Doubling Down on BRCA-Mutated CancerAndrea E Wahner Hendrickson, Scott H Kaufmann, Elizabeth M Swisher
Cancer Medicine|May 12, 2016
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trialsSeongseok Yun, Nicole D Vincelette, Myke R Green, et al.
Journal of Palliative Medicine|May 25, 2018
Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated PatientsJason D Doles, Kelly A Hogan, Jennifer O'Connor, et al.
Cancer Research|April 4, 2013
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA statusCatherine J Huntoon, Karen S Flatten, Andrea E Wahner Hendrickson, et al.
Investigational New Drugs|April 2, 2013
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignanciesErin Schenk, Andrea E Wahner Hendrickson, Donald Northfelt, et al.
Rare Tumors|May 7, 2021
An unusual case of aggressive malignant spread of epithelioid hemangioendotheliomaAshley D Hickman, Evandro D Bezerra, Anja C Roden, et al.
Current Treatment Options in Cardiovascular Medicine|March 3, 2018
Cardiovascular Concerns in BRCA1 and BRCA2 Mutation CarriersKelly C Gast, Paul V Viscuse, Somaira Nowsheen, et al.
Gynecologic Oncology|June 15, 2026
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomesRiham Suleiman, Shilpa Mokshagundam, Matthew S Block, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 4, 2021
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitizationUpasana Ray, Debarshi Roy, Ling Jin, et al.
Gynecologic Oncology|July 13, 2023
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?Anousheh Shafa, A Brooke Watkins, Michaela E McGree, et al.
Pageof 6